NTK1 Stock Overview
A venture capital firm specializing in seed, growth capital, early and mid stage investments. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
EMV Capital plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.49 |
| 52 Week High | UK£0.81 |
| 52 Week Low | UK£0.49 |
| Beta | 1.67 |
| 11 Month Change | -9.63% |
| 3 Month Change | -17.29% |
| 1 Year Change | -22.54% |
| 33 Year Change | -60.65% |
| 5 Year Change | -19.34% |
| Change since IPO | -97.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTK1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -1.0% | -0.02% |
| 1Y | -22.5% | -7.3% | 8.2% |
Return vs Industry: NTK1 underperformed the German Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: NTK1 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| NTK1 volatility | |
|---|---|
| NTK1 Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: NTK1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NTK1's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 29 | Ilian Iliev | www.emvcapital.com |
EMV Capital plc is a venture capital firm specializing in seed, growth capital, early and mid stage investments. The firm focuses to invest in sustainability, life science, technology, transformative biomedical, deep tech, semiconductors, industrials, robotics, AI and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases.
EMV Capital plc Fundamentals Summary
| NTK1 fundamental statistics | |
|---|---|
| Market cap | €13.48m |
| Earnings (TTM) | -€3.58m |
| Revenue (TTM) | €2.18m |
6.2x
P/S Ratio-3.8x
P/E RatioIs NTK1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTK1 income statement (TTM) | |
|---|---|
| Revenue | UK£1.81m |
| Cost of Revenue | UK£374.00k |
| Gross Profit | UK£1.44m |
| Other Expenses | UK£4.41m |
| Earnings | -UK£2.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 79.33% |
| Net Profit Margin | -164.23% |
| Debt/Equity Ratio | 6.1% |
How did NTK1 perform over the long term?
See historical performance and comparison